Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours

被引:0
作者
Kevin Litchfield
Brenda Summersgill
Shawn Yost
Razvan Sultana
Karim Labreche
Darshna Dudakia
Anthony Renwick
Sheila Seal
Reem Al-Saadi
Peter Broderick
Nicholas C. Turner
Richard S. Houlston
Robert Huddart
Janet Shipley
Clare Turnbull
机构
[1] The Institute of Cancer Research,Division of Genetics and Epidemiology
[2] The Institute of Cancer Research,Divisions of Molecular Pathology and Cancer Therapeutics
[3] Inserm U 1127,undefined
[4] CNRS UMR 7225,undefined
[5] Sorbonne Universités,undefined
[6] UPMC Univ Paris 06 UMR S 1127,undefined
[7] Institut du Cerveau et de la Moelle épinière,undefined
[8] ICM,undefined
[9] The Breakthrough Breast Cancer Research Centre,undefined
[10] The Institute of Cancer Research,undefined
[11] Academic Radiotherapy Unit,undefined
[12] The Institute of Cancer Research,undefined
[13] William Harvey Research Institute,undefined
[14] Queen Mary University London,undefined
来源
Nature Communications | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Testicular germ cell tumours (TGCTs) are the most common cancer in young men. Here we perform whole-exome sequencing (WES) of 42 TGCTs to comprehensively study the cancer's mutational profile. The mutation rate is uniformly low in all of the tumours (mean 0.5 mutations per Mb) as compared with common cancers, consistent with the embryological origin of TGCT. In addition to expected copy number gain of chromosome 12p and mutation of KIT, we identify recurrent mutations in the tumour suppressor gene CDC27 (11.9%). Copy number analysis reveals recurring amplification of the spermatocyte development gene FSIP2 (15.3%) and a 0.4 Mb region at Xq28 (15.3%). Two treatment-refractory patients are shown to harbour XRCC2 mutations, a gene strongly implicated in defining cisplatin resistance. Our findings provide further insights into genes involved in the development and progression of TGCT.
引用
收藏
相关论文
共 125 条
[1]  
Bray F(2006)Interpreting the international trends in testicular seminoma and nonseminoma incidence Nat. Clin. Pract. Urol. 3 532-543
[2]  
Ferlay J(2014)Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing Urol. Oncol. 32 33.e31-33.e36
[3]  
Devesa SS(2013)Early development of the metabolic syndrome after chemotherapy for testicular cancer Ann. Oncol. 24 749-755
[4]  
McGlynn KA(2013)Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network Fertil. Steril. 100 673-680
[5]  
Moller H(2014)Risk of second primary cancers after testicular cancer in East and West Germany: a focus on contralateral testicular cancers Asian J. Androl. 16 285-289
[6]  
Ruf CG(2012)Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer Br. J. Cancer 107 1853-1863
[7]  
de Haas EC(1996)Reviews of chromosome studies in urological tumors.3. Cytogenetics and genes in testicular tumors J. Urol. 155 1531-1556
[8]  
Bujan L(1982)Specific chromosome change, I(12p), in testicular-tumors Lancet 2 1349-1349
[9]  
Rusner C(1983)I(12p)—specific chromosomal marker in seminoma and malignant teratoma of the testis Cancer. Genet. Cytogenet. 10 199-204
[10]  
Nitzsche B(1998)Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes J. Mol. Med. 76 648-655